Working… Menu
Trial record 12 of 147 for:    visilizumab

Research Study of Visilizumab for Treatment of Glucocorticoid- Refractory Graft Versus Host Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00032279
Recruitment Status : Unknown
Verified October 2003 by Facet Biotech.
Recruitment status was:  Active, not recruiting
First Posted : March 18, 2002
Last Update Posted : June 24, 2005
Facet Biotech
Information provided by:
Facet Biotech

Brief Summary:
The purpose of this phase II study is to evaluate an investigational monoclonal antibody for the treatment of glucocorticoid-refractory Graft Versus Host Disease (GVHD). Patients diagnosed with GVHD who have not responded satisfactorily to, or are intolerant of, treatment with standard agents will be considered for entry. Patients will be allowed to continue on their other immunosuppressive drugs at stable doses during the trial. The research is being conducted at up to 20 clinical research sites in the US.

Condition or disease Intervention/treatment Phase
Graft-vs-Host Disease Drug: Visilizumab Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 80 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II, Multicenter Clinical Trial Evaluating the Use of Humanized Monoclonal Anti-CD3 Antibody Visilizumab(Nuvion) as Second-line Therapy for Glucocorticoid-Refractory, Acute Graft-Versus-Host Disease
Study Start Date : March 2002

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
  • Grade II to IV GVHD
  • Clinical findings: skin thickening, joint contraction, oral ulceration, diarrhea.
  • History of allogeneic hematopoietic cell transplant (HCT).
  • Patients must have failed to respond or clearly progress to previous therapy on or before day +100 posttransplant.
  • Patients must have adequate renal, hepatic, cardiac function and hematologic values

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00032279

Layout table for location information
United States, California
City of Hope National Medical Center
Duarte, California, United States, 91910
Stanford University Medical Center
Stanford, California, United States, 94305-5623
United States, Florida
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida, United States, 33612
United States, Indiana
University Hospital
Indianapolis, Indiana, United States, 46202
United States, Massachusetts
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02115
University of Massachusetts Medical School
Worcester, Massachusetts, United States, 01605
United States, Missouri
Washington University School of Medicine
St. Louis, Missouri, United States, 63110
United States, New York
The New York Hospital Cornell Medical Center
New York, New York, United States, 10021
Westchester Medical Center
Valhalla, New York, United States, 10595
United States, North Carolina
Duke University
Durham, North Carolina, United States, 27705
United States, Ohio
Cleveland Clinic Foundation
Cleveland, Ohio, United States, 44195
Ohio State University
Columbus, Ohio, United States, 43210
United States, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232-6310
United States, Texas
Baylor University Medical Center
Dallas, Texas, United States, 75246
Baylor College of Medicine
Houston, Texas, United States, 77030
MD Anderson Cancer Center
Houston, Texas, United States, 77030
United States, Washington
Fred Hutchinson Cancer Research Center
Seattle, Washington, United States, 98109
Sponsors and Collaborators
Fred Hutchinson Cancer Research Center
Facet Biotech

Layout table for additonal information Identifier: NCT00032279     History of Changes
Obsolete Identifiers: NCT00042744
Other Study ID Numbers: 1589
First Posted: March 18, 2002    Key Record Dates
Last Update Posted: June 24, 2005
Last Verified: October 2003
Additional relevant MeSH terms:
Layout table for MeSH terms
Graft vs Host Disease
Immune System Diseases
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Immunologic Factors